NFKK 2014

Invited Speakers

Paolo Arosio 

Professor of Molecular Biology at the Medical school of the University of Brescia, in North Italy. Since the beginning of his career his scientific interests have been focused on iron proteins, in particular on ferritin. He was initially involved in the identification and characterization of the H and L subunits that compose the cytosolic ferritins and in the study of the mechanism of ferritin iron incorporation. He participated also in the  identification and characterization  of a new ferritin specifically expressed in the mitochondria, which is highly expressed in sideroblasts. Recently he has been studying a genetic disease involving  ferritin L-chain, named neuroferritinopathy which is part of the NBIA diseases (Neurodegeneration with brain iron accumulation). He is presently interested also in the regulation of hepcidin expression and in particular in the use of  heparins as hepcidin antagonists with potential clinical application. He is co-author of about 200 publications. He is co-organizer of the next European Iron Club, in Verona 11-14 September, 2014.

Kaj Blennow

Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, and Professor in Clinical Neurochemistry at the Sahlgrenska Academy, Mölndal campus at University of Gothenburg, Sweden. The major research areas are cerebrospinal fluid biochemical markers, clinical proteomics, and the neurochemical pathogenesis of Alzheimer’s disease and other brain disorders. He has published more than 600 original research papers and 90 review articles in peer-reviewed journals, and has a citation H-index of 81.

He has received a number of scientific awards, such as The CINP Award (1992), the IPA Research Award (1993), the Alois Alzheimer Research Award (2001), the ECNP Clinical Research Award (2010), and the Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research (2011).

John Burthem

Having trained in the UK at Liverpool then Oxford, I am now a Consultant Haematologist at Manchester Royal Infirmary leading the laboratory diagnosis for the University Clinical Haematology Department. I am also Clinical Senior Lecturer at Manchester University leading a Research Group studying cell signalling in chronic lymphocytic leukaemia. My long-standing interest in haematological morphology and microscopy has lead to positions with UK NEQAS(H) presently chairing the Morphology Special Advisory Group, being part of the design team, and now leading the Digital CPD scheme for that group. I also act as Deputy Editor of the European Haematology Association Teaching and Online Learning Group (EHA-TOL). I have a particular interest in harnessing digital tools to assist teaching and decision support in morphological diagnosis through association with UK NEQAS, Manchester Metropolitan University and my own website (  

Daniel Elenius Madsen

Unit for Thrombosis Research, University of Southern Denmark and Department of Clinical Biochemistry, Hospital of Southwest Jutland, Esbjerg

MSc Biomedicin (MD), 2011, PhD Student 2011 (- 2014)

I am currently a Ph.D. student at University of Southern Denmark, Institute of Public Health, Unit for Thrombosis Research and will finish my PhD in 2014.

Previously I was employed as a Project worker at Region of Southern Denmark, Hospital of Southwest Jutland, Department of Clinical Biochemistry.

I have been Course responsible for the following courses, “Immunology – Interplay with the coagulation system” and “Introduction to ELISA – Practical and methodological aspects” at University of Southern Denmark.

Elisabet Eriksson Boija

PhD Biochemistry. My positions at Equalis, the Swedish organisation for external quality assurance for the healthcare system, are as SKUP coordinator and as clinical biochemist in general clinical chemistry and coagulation. SKUP is a Scandinavian project working with evaluations of POC-instrument being on, or trying to get onto, the Scandinavian market. SKUP was founded in 1997 and is now acknowledged worldwide for its independent trials of instruments intended for patient near care.

Monika H. E. Christensen

Resident Dept. of Internal Medicine Haukeland University Hospital Bergen, Norway.

2001 (M.D.), University of Würzburg, Germany
2013 PhD, University of Bergen, Norway.

Jan 02 - Aug 03 Internship, Depts. of Internal Medicine and Surgery, Harstad Hospital, and General Practice in Bardu, Norway
Aug 03 - Feb 05 General practitioner in Bardu and Salangen, Norway
Mar 05 - Oct 06 Resident, Hormone Laboratory, Haukeland University Hospital, Bergen, Norway
Oct 06 - Oct 07 Resident, Dept. of Internal Medicine, Haukeland University Hospital
Oct 07 - Aug 09 Resident, Hormone Laboratory, Haukeland University Hospital
Sept 09 - Aug 013 Research Stipend from the University of Bergen
March 13 - sept 13 Academic visitor at the School of Population Health, The University of Auckland, New Zealand
March 14 - June 14 Resident, Hormone Laboratory, Haukeland University Hospital
June 14 - dd Resident, Dept. of Internal Medicine, Haukeland University Hospital

Ingemar Ernberg

Made his PhD-thesis at the Karolinska Institutet with George Klein in 1979, finished his MD in 1984, studied abroad in Omaha, Nebraska 1986 and at the MRC Laboratory of Molecular Biology in Cambridge UK 1988-1990. In 1996 he was appointed professor of Tumor Biology at Karolinska Institutet. He was secretary of science at the Swedish Cancer Society 1983-93.

He was the first chair of the newly formed  Department Microbiology and Tumorbiology Center (MTC) of Karolinska 1993-1999. He is now the chairperson for the Karolinska Institute (KI) Cancer Network organizing 120 research groups, as well as coordinator for KI collaborations with China, while he heads his research group of 8 at MTC, KI. He is also chairing National School for PhD in clinical cancer research (NatiOn), the KI PhD program in Tumor Biology and Oncology. He is the iniator and chair of the National Network for Computation and Systems Biology in Cancer Research (COMPAS).  He has been the supervisor of 23 PhD-students.

Ingemar Ernbergs work deals with tumor viruses in man, transcritional regulation (HIV, EBV), epigenetics (methylation) and recently also gut flora. One seminal discovery established that the B-lymphocyte is the site of EBV-latency in vivo (Gratama et al, PNAS, 1988). More recent interests have dealt with genomic signatures and global gene expression profiles, as well as designing methods to allow quick analysis of the gut normal flora.  This has lead to an increasing interest in tissue biology, self organization of biological systems and the possibilities and limits of simulations in silico as an additional scientific tool. 

He as been awarded a Wellcome Trust Fellowship Award 88-89,  a fellowship from the Cancer Research Institute, New York 78-80, Honorary professor  at JiaTong Univ, Shanghai 2012, P.R. of China award for International Cooperation in Science and Technology and the PR China. National friendship Award 2007, the Jan Pontén memorial lecture, Swedish Medical association, 2003, and the Engelhardt Memorial Lecture, Moscow 2004.

Anders Grubb

Professor in Clinical Chemistry, Lund University, Sweden. Main research areas: Cystatin C as a marker for Glomerular Filtration Rate. The molecular mechanism for production of amyloid fibrils, particularly cystatin C fibrils.

Ulf Gyllensten

Ph.D. in Genetics, University of Stockholm 1984, Postdoctoral fellow, University of California, Berkeley 1986, Associate Scientist, Cetus Corporation, California 1988, Full Professor in Medical Molecular Genetics, Uppsala University 1993, Co-director for National Genomics Infrastructure, a core facility for Genotyping and DNA sequencing 1998, Director of the Rudbeck Laboratory 2010. Research in epidemiology and genetics of cervical cancer and identification of the genetic basis of human clinical quantitative characters.

David Hanlon

Ph.D., Director, Business Development and Strategic Collaborations

Dr. Hanlon joined Quanterix in 2008 to identify unmet market opportunities that would benefit from the Company’s Single Molecule Array (Simoa) technology platform.  Prior to Quanterix, Dr. Hanlon led several external research collaborations at Cytyc to discover novel biomarkers of cervical neoplasia, as well as an internal team focused on marker validation and the development of diagnostic assays.  Dr. Hanlon was Director, R&D at VisEn Medical and Project Manager at Proteome, where he led a team of scientists developing protein-centric databases for comparative and functional genomic applications.  He also served as Director of Neuroscience at Oncogene Research Products where he developed a life science portfolio consisting of neurochemical and immunological products.   Dr. Hanlon received his Ph.D. from the University of Illinois, Urbana-Champaign and was a postdoctoral research fellow at Harvard University and the University of California, San Diego.  He obtained a B.S. degree in Biochemistry from Worcester Polytechnic Institute.

John Hardy

Chair of Department of Molecular Neuroscience and Reta Lila Weston Laboratories, UCL  Institute of Neurology UK 

John Hardy received his degree in Biochemistry from Leeds in 1976 and his PhD from Imperial College in Neuropharmacology in 1979.  He did postdocs at the MRC Neuropathogenesis Unit and the Swedish Brain Bank, in Umea,  where he started to work on Alzheimer’s disease.  In 1985 he took the job of Lecturer in Biochemistry and Molecular Genetics at St Mary’s Hospital, Imperial College, where he began working on the genetics of Alzheimer’s disease.  In 1991 he led the group which found the first mutation in the amyloid gene which caused Alzheimer’s disease.  This finding led him and others to formulate the amyloid hypothesis for the disease.  In 1992 he moved to the United States, to the University of South Florida.  In 1996 he moved to the Mayo Clinic where he became Chair of the Department of Neuroscience in 2000.  In 1998 he was part of the consortium which identified mutations in the tau gene in Pick’s disease.  In 2001 he moved to the NIH to become the Chief of the Laboratory of Neurogenetics, where he was part of the group which found triplications in the synuclein gene caused Parkinson’s disease.  He returned to the Department of Molecular Neuroscience at the Institute of Neurology in 2007.  He has won the Allied Signal, Potamkin, MetLife  and Kaul Prizes, for his work on Alzheimer’s disease and the Anna Marie Opprecht Prize for his work on Parkinson’s disease.  More recently he was awarded the 2011 Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research and the IFRAD 2011 European Grand Prize for Alzheimer's Research.  In 2014 he has been awarded The Dan David Prize endowed by the Dan David Foundation,  headquartered at Tel Aviv University;  the Thudichum Medal from the Biochemical Society and  is the recipient of the 3rd Lord Brain Memorial Medal.  He has been elected a member of the Academy of Medical Sciences and has been awarded an honorary MD by the University of Umea, Sweden.  He was made an FRS by the Royal Society in 2009 and in 2010 was awarded an honorary Doctor of Science degree by the University of Newcastle.  He has three adult children and three grandchildren who live in the US.

Hans Hasselbalch 

Professor. Consultant Haematologist  at the Department of Haematology, Roskilde Hospital, University of Copenhagen. He is former chairman of the Danish Study Group of Chronic Myeloid Neoplasms and   member of the Nordic  Myeloproliferative Study Group (NMPD) .  For many  years  his professional interests have focused upon chronic myeloid neoplasms (MPNs) and benign haematological diseases , in particular primary immune thrombocytopenia and autoimmune haemolytic anaemias.  He has been  principal investigator and leader of the Danish ITP- Multicenter Study randomizing newly diagnosed ITP-patients between dexamethasone monotherapy and dexamethasone + rituximab. His main research in MPNs is focusing upon integrated molecular (eg. gene expression profiling, epigenetics,SNPs) and immune cell studies in MPN patients before and during treatment with interferon-alpha2 (IFN-alpha2) and novel targeted therapies , including JAK1-2 inhibitor and histone deacetylase inhibitor treatment. In this regard he is co- investigator of a Danish Multicenter Study on low-dose IFN-alpha2 in the treatment of MPNs and was principal investigator in  an International Multicenter Study on Vorinostat in the treatment of polycythaemia vera and essential thrombocythaemia. He is currently initiating studies on combination therapies with interferon-alpha2 and JAK2-inhibitors and statins as well.  

Niels H. H. Heegaard, MD, DSc

Professor and Consultant,  Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark

Group leader: Analytical Protein Chemistry, Department of Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark


  • Molecular diagnostics for human diseases
  • High resolution analytical protein chemistry
  • Mechanisms of protein conformational diseases
  • Post-translational modifications of proteins and peptides
  • Microparticle proteome analysis
  • Circulating micro-RNA in cancer, neurodegeneration, and immunoinflammation

Camilla Hesse

Biomedical scientist, PhD and programme director for the biomedical laboratory science (BLS) programme at Sahlgrenska Academy, Gothenburg University.

Camilla has a background in the field of transfusion medicine and has focused her work on blood components and transfusion safety.

As a programme director for the BLS programme, she aims to develop the programme to meet the future needs in the field of laboratory medicine.

Nete Hornung

MD, PhD. Dept. of Clinical Biochemistry RegionalHospital Randers, Denmark.

Graduation from Faculty of Health Science, Aarhus University, January 1991

Resident and training in clinical biochemistry:

January 1993 to August 1994: resident Nykøbing Mors Hospital

August 1994 to December 2000: Training in clinical biochemistry at the Departments of Clinical Biochemistry, Aarhus University Hospitals, NBG and TBG.

Authorisations from National Board of Health, Denmark:

August 1994 permission to practice independently as a Physician.

December 2000 authorisation as Specialist of Clinical Biochemistry.

Doctor of Philosophy:

August 1998: Faculty of Health Science, Aarhus University: Effects of Cyclosporine A and rapamycin on normal human B lymphocytes in vitro".

Other Qualifications:

Trained Surveyor at the Danish Accreditation and Metrology Fund – DANAK

2008-2012 Chairman of the board of The Danish Society for Clinical Biochemistry

Fredrik Höök

Obtained his Doctors degree of Physics in 1997 from an inter-disciplinary PhD program between the Department of Applied Physics and the Department of Biochemistry and Biophysics at Chalmers and Gothenburg University, Gothenburg, Sweden. After that he had a one and a half year assistant professor position in surface biotechnology at Cell and Molecular Biology, Gothenburg University, which was in 2000 transferred into an assistant professor position in Biological Physics at the Department of Applied Physics at Chalmers. In 2004 he was appointed a professor position in Nanoscience for Biophysics at the Department of Physics at Lund University and in 2007 he was appointed full professor in Physics at Chalmers.

His research has focused on the development of surface-based bioanalytical tools, such as QCM-D, localized SPR and more recently TIRF microscopy and imaging ellipsometry and their combination with microfluidics for fundamental studies of cell-membrane mimics but also for use in diagnostic, drug-screening applications and the development of drug delivery concepts. Efforts are presently focused on (i) new methods with single molecule sensitivity for studies of single liposomes and individual membrane proteins, (ii) microfluidic platforms for detergent-free separation of cell-membrane components and (iii) sophisticated surface modifications and nanofabrication schemes to facilitate improved analysis of supported cell-membrane mimics, membrane proteins and virus binding.

Fredrik Höök is presently heading the Biological Physics division at Chalmers, which is composed of around 20 scientists on various levels (~10 PhD students, ~9 postdocs, 2 assistant/associate professors). He has published around 120 scientific papers, has a H-index of 40, with 20 papers cited more than 100 times and more than 7000 citations in total. He is also co-founder of the companies Q-Sense AB and LayerLab AB. He has been awarded the Akzo Nobels Nordic research award in 2002, an individual grant for the Advancement of Research Leaders and in 2005 by the Swedish Foundation for Strategic Research and the prestigious Göran Gustafsson prize in Physics in 2012 by the Royal Swedish Academy of Sciences

Martina Jürs

As Vice-President of The Danish Association of Biomedical Laboratory Scientists (BLS) I have been elected by our 6500 members to represent the profession’s interests.

Focus areas of my work are:
- The BLS profession’s competencies
- The BLS profession’s identity
- The BLS profession’s education
- Further education for BLS
- Research within the BLS profession
- BLS professional ethics
- BLS professional management

A central part of my job is to develop the BLS profession as a diagnostic partner. The goals are to:

1. Ensure that BLS competencies are applied in the most optimal way within

the health care sector - both in regards to existing and future job areas

2. Create a mind set within the profession of being a diagnostic partner – meaning seeing oneself as part of a patient centered team, being co-responsible for the patient’s treatment and proactively taking on new ways of working in order to optimize the patient’s treatment course.

Birgitta Kallberg

Head of Unit at Clinical Chemistry Laboratory, Sahlgrenska University Hospital, Sweden responsible for the laboratory operations at Molndal Hospital and Nordhem Clinic and senior member of the operators management 

Head of the Customer & POCT team at Clinical Chemistry Laboratory and the strategic procedures related to this field.
Extensive experience in managing enterprise-wide projects in various fields such as process-business development, IT system coordination, procurements and more.
MSc, in Health Services Administration and ongoing studies for an MSc in Leadership in the public sector at School of Executive Education at University of Gothenburg

Mikael Kubista

Dr Kubista is the head of the department of gene expression at the institute of Biotechnology of the Czech Academy of Sciences, and founder and CEO of the TATAA Biocenter ( He was one of the pioneers contributing to the development of quantitative real-time PCR (qPCR) and introduced qPCR for single cell expression profiling.  He led the development of reagents for high throughput single cell expression profiling and quality control at TATAA. He also developed qPCR tomography for intracellular expression profiling.

Päivi Laitinen

Chief Chemist in HUSLAB, Laboratory of Helsinki University Hospital and in that role she is responsible of the technical and analytical issues as well as acquisitions of Clinical Chemistry and Haematology department of HUSLAB. She is also involved in a building and planning of the new laboratory building for HUSLAB.

Päivi Laitinen obtained her PhD in Biochemistry and Master’s degree in Health Care Administration from Oulu university. Her scientific interests focus presently mainly on prenatal screening and evaluation of laboratory methods as well as the use and implementation of cardiac markers.

Päivi Laitinen has been actively involved in the activities of the scientific societies of clinical chemistry and laboratory medicine at the national, European and international level. She served as a member of Board of the Finnish Society of Clinical Chemistry, Vice-President and President 1998-2002 of the Society. She has been a member of the Finnish Clinical Chemistry Register Committee (EC4) 1998-2002. The international activities include memberships European Communities Confederation of Clinical Chemistry (EC4) Board (2003-2005) and Scandinavian Society of Clinical Chemistry Board (1998-2002) as well as membership of the IFCC Awards Committee (2003-2005). At present she is chairing an EFLM Working Group on Cardiac Markers and IFCC Nominations Committee. Päivi Laitinen was the Secretary of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Executive Board in 2006-2011.

Ulf Landegren, MD PhD

Professor of molecular medicine in Uppsala and develops molecular tools for analyzing macromolecules. He is a member of EMBO, the Royal Swedish Academy of Sciences, and the SAC for European Academies, several scientific advisory boards, and vice-director of the SciLifeLab. He has authored 170 peer-review publications and 35 patents. His technologies have been licensed to 11 biotech companies, and his lab has spun out five biotech companies.

Anders Lindahl

MD, Ph.D. is professor and consultant at the Institute of Laboratory Medicine at Sahlgrens University Hospital, Gothenburg Sweden. Since 2005 he is the Director of the Clinical Chemistry laboratory of Sahlgrenska University Hospital. He is the medical director of the cell transplantation unit and head of a research group focused on cartilage repair and chondrocyte differentiation. Anders Lindahl graduated at the Medical Faculty of the University of Gothenburg in 1979, completed his internship in 1982 and received his Board certificate in Clinica Chemistry in 1992. He received his Ph.D. degree in 1986 from University of Gothenburg. He upheld a research fellow position in the laboratory of Dr Howard Green at the Department of Cell Biology, Harvard Medical School, Boston, MA US 1987–1988 with a work focused on gene therapy. His research on human chondrocytes commenced in 1985 and he and Dr Lars Peterson and Mats Brittberg performed the pioneering work introducing autologous chondrocyte transplantation (ACT) for the treatment of cartilage defects in the knee. The article in New England Journal of Medicine (331:889-895, 1994) was by Harvard Health Letter nominated as one of the ten most important scientific papers that year. He has written over 130 articles in the field of chondrocyte regeneration and stem cells and Dr Lindahl and collaborators have until today treated over 1500 patients with ACT. Dr Lindahl has supervised 15 PhD students and 5 post-docs and currently 2 PhD students are under supervision. He has several national and international grants with a yearly budget of around €500.000. 

Bertil Lindahl, MD, PhD

Professor in Cardiology, Uppsala University, and is the author of more than 150 original articles and more than 50 review articles or book chapters, mainly in biochemical markers and quality registries in acute coronary syndromes. He is member of Task Force for the Universal Definition of Myocardial Infarction and the committee for the National Guidelines for Cardiac Care. He has also participated in the scientific advisory boards for a number of diagnostic companies. 

Per Lindahl

Professor at the Wallenberg Laboratory at the Sahlgrenska akademy . After post-graduate studies in Christer Betsholtz lab, he started his own research group in 1999 in Gothenburg. The research is focused on the role of tumor suppressors and oxidative damage in cardiovascular disease and cancer. His group conducts translational studies using transgenic mice as their primary model system.   

Simon Lovestone

is Lead for the NIHR Translational Research Collaboration in Dementia – a network of six centres in England - and Professor of Translational Neuroscience at Oxford University. He has research interests in the regulation of tau phosphorylation, dementia therapeutics and in genetic and other biomarkers of Alzheimer’s disease. Underpinning all these studies is the use of informatics and the challenges of extracting value from very large variable datasets.

Christian Löwbeer, MD, PhD,

Specialist in Clinical Chemistry. Senior Physician, Department of Clinical Chemistry, Aleris Medilab, Täby. Affiliated to the Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm. National Director of Studies in Clinical Chemistry. Research field: biochemical markers for myocardial damage. Co-author of 30 scientific publications. Career track at Karolinska Institutet – teaching: completed eleven weeks training in university-level teaching.

Niklas Mattsson

University of Gothenburg, Sweden/University of California, San Francisco, USA

Medical degree (MD), May 2005, Doctor of Philosophy (PhD), Medicine, December 2011

My current Post doc. position as of December 2012 is a position shared between University of Gothenburg, Sweden and University of California, San Francisco, USA. I am employed by the University of Gothenburg, Sweden and funded by a grant from the Swedish Research Council. The research projects are conducted in the US and Sweden and concerns fluid and imaging biomarkers for Alzheimer’s disease. The principal investigators are Professors Michael Weiner (Center for Imaging of Neurodegenerative Diseases, UCSF) and Henrik Zetterberg (University of Gothenburg).

My previous position from 2008 – 2012 was as a Resident doctor at Clinical Chemistry, Sahlgrenska University Hospital, Göteborg and Mölndal, Sweden Research within the clinical position financed by the Sahlgrenska University Hospital and the University of Gothenburg. My internship from 2006-2008 took place at Sahlgrenska University Hospital, including 6 months of internal medicine, 6 months of surgery, 3 months of psychiatry and 6 months of general practice, and 6 months research at University of Gothenburg, Institute of Neuroscience and Physiology.

I have lectured on neurochemistry, psychiatry, and clinical chemistry at the Medical Faculty, University of Gothenburg. Furthermore I have been invited lecturer at several academic institutions in Sweden and abroad, including the US and Australia, and am a supervisor of PhD students.

Andreas Matussek

Associate professor in Medical microbiology at Linköping University, Director of Laboratory services and Medical director of the Clinical microbiology laboratory in Jönköping County Council.

His research is translational and focuses mainly on clinical microbiology and infection control. The objectives are to minimize nosocomial infections, optimize diagnostics and enhance clinical outcomes and patient safety.

In the field of Laboratory services he works process oriented enabling new innovative strategies to deliver cohesive laboratory results.  This includes integration of laboratory disciplines to continuously enhance service levels to meet future patient needs and thereby controlling costs.

Olle Melander

MD, PhD. Professor of Internal Medicine at Lund University and consultant at the Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden. His research is focused on improvement of cardiovascular risk stratification and identification of potentially life style and drug modifiable mechanisms behind diabetes and cardiovascular disease. He is author of >200 original publications, has >10 000 citations and a h-index = 41.  

Mirja Mindemark 

Biomedical scientist with background in clinical chemistry.

PhD in biomedical laboratory science with focus on the use of laboratory analyses in Sweden, specifically from the perspective of quality and cost-effectiveness in test utilization and the beneficial influence of diagnostic tests on both patient care and overall health care costs.

Senior Account Manager at Roche Diagnostics Scandinavia with focus on medical value within the area of Core Lab & Critical Care.

Rafael Molina

He was worn in Barcelona, in September 1955, graduate in Medicina in the School of Medicina of University of Barcelona in 1979, and did the speciality board on Clinical Pathology in the Hospital Clinic of Barcelona (1980-1983).

In 1983 started to work as specialist in the Laboratory of Clinical biochemistry in Hospital Clinic, being in charge of the Immunoassay Unit, and from 1992 is the Head of the Oncobiology Unit. In 1989 Dr Molina was Assistant Professor in the Department of Oncology, Health Science Center at San Antonio, Texas, learning techniques of Molecular Biology and Immunohistochemistry. Since 1996 is Assistant Professor of Biochemistry and Molecular Biology of the University of Barcelona and from 2002, president of the Biochemist Section of the Catalonian Academy of Medical Sciences. Since 2002 Dr Molina is board member of the ISOBM (International Society of Oncology and Biomarkers), President from 2012 and member of the editorial board of different journals: Tumor Biology, Journal of Biological Markers and Clinical Biochemistry. Likewise, Dr. Molina is chairman an active member of the European Group on Tumor markers (EGTM) and has been contribute to the publication of guidelines about the tumor marker use in Breast cancer and lung cancer.

Dr Molina is working in laboratory Oncology, being his main field of interest the clinical use of tumor markers. He is author of more than 175 original articles and chapters of books. Dr Molina has been member of the organizing Committee of 15 Symposiums and 10 annual Courses about the clinical utility of tumor markers. His main concern is to approach the laboratory to clinicians and to obtain the maximum utility of laboratory test, that can help, both the doctor and the patient.

Lorenzo Monserrat

Studied Medicine in Santiago de Compostela. Specialist in Cardiology and PhD in A Coruña University. Research Fellowship in Cardiomyopathies at St George´s Hospital, London. Researcher of the Galician Health Service and Chief of the Inherited Cardiovascular Diseases Reference Unit in A Coruña University Hospital. Author of >90 papers on inherited cardiovascular diseases and cardiovascular genetics. Founder and CEO of Health in Code.

Martin Möckel, Univ.-Prof. Dr. 

FESC, FAHA graduated  from the Medical School of the Free University Berlin in 1991. His finalized his doctoral thesis on stress Doppler echocardiography in 1992 with “summa cum laude”. After years of residency in Cardiology and Intensive Care Medicine he became specialist of Emergency Medicine 1995, Internal Medicine in 1998, Special Internal Intensive Care Medicine in 2000 and Nephrology in 2001. He started training of Interventional Cardiology and became consultant in 2001 after finalization of his Ph.D. thesis. In 2003 he specialized in Cardiology. In 2007 he was awarded as extraordinary Professor of Medicine and 2009 he became adjunct Professor at the School of Epidemiology of the JCU, Townsville, QLD, Australia.

In 2010 Prof. Möckel was appointed as head of the Division of Emergency Medicine at Charité – Universitätsmedizin Berlin. In 2012 he became full Professor of Cardiology. Up to now, Professor Möckel  is the head of Emergency Medicine and Acute Cardiovascular Care at Charité. His research focus lay on processes in acute care, interventional therapy of AMI, diagnostic strategies in acute cardiac care and the cardiorenal syndrome. Prof.  Möckel has led numerous investigator initiated and multicenter trials as PI of the Charité and has published more than 100 peer reviewed full research papers.

Ebba Nexø, MD, Dr.Med.Sci.

She holds a professorship in clinical biochemistry at the University of Aarhus, and she has long standing achievements within the areas of vitamins and growth factors. Notably she has contributed with both basic and clinical aspects related to vitamin B12 often in collaboration with international colleagues and as part of several EU-projects. She has served as chairman for NFKK, and she has chaired the Danish MRC. In addition she has served as consultant on vitamin B12 amongst others for FAO and NIH.

Mats Ohlson

1:e kemist, Ph D, at the Department of Clinical Chemistry at the Sahlgrenska University Hospital, Gothenburg, Sweden.
Mats’ main interest is the analysis of drugs and drugs of abuse, both concerning the choice of technical platforms and setups, as the regulation and the quality assurance of the analytes. He is also involved in the prevention of problems in the pre- and post-analysis steps.
Mats is, as the chairman of the Swedish Association of Clinical Biochemists (SSKF), working on the formation of a Swedish syllabus for scientists in laboratory medicine according to the EC4RC.

Tom Pettersson

Clinical Biochemist PhD

Born 1950 in Finland, Finnish citizen, but professionally active and living in Sweden, Stockholm since 1977. Educational background in chemistry from Åbo Akademi, Department of Natural Sciences, Finland. Specialized in Clinical Biochemistry from Turun Yliopisto, Finland. Dissertation in Medical Diagnostics on Thyroid Hormone Measurements and Metabolism at Karolinska Institutet, Sweden 1989. Post Doc research fellow at Russel l Grimwade School of Medical Biochemistry and Molecular Biology at Melbourne University, Australia. Served as Principal Clinical Biochemist at Danderyd Hospital public sector healthcare of Stockholms Läns Landsting, later as head of Clinical Chemistry department of the private Medical Laboratory Calab, Stockholm, followed by role as Head of Development at the private medical laboratory Nova Medical, transformed to Capio Diagnostics and later to the Pan-European laboratory enterprise Unilabs. Professionally focused on laboratory design, integration and consolidation, process management and control, analytics and automation design as well as value engineering, quality management, education, learning and innovation management. Introduced Lean, Six Sigma into the clinical laboratory quality management portfolio from 2005 and is presently operating as independent healthcare professional driving Innovation, Learning and Lean in the medical laboratory.

Sidsel Rødgaard-Hansen

Dept. of Clinical Biochemistry, Aarhus University Hospital, Denmark

Medical degree (MD), January 2007, PhD-Fellow, Medicine

I currently hold a position at Department of Clinical Biochemistry at Aarhus University Hospital, Denmark. The postion is a combination of medical Specialist training in clinical biochemistry and performing my PhD project entitled “Marcrophage Biomarkers in Obesity and Liver Disease.

I am part of the CD 163 Research Group, i.e. Inflammation Research engaged at investigating how inflammation affects the development of obesity-related diseases such as type-2 diabetes and non-alcoholic fatty liver disease, and how inflammation accepts cancer. The goals of this group are to take new discovery from the biochemical level into clinical use (diagnostic assays, therapeutic targets). The principal investigator of this group is Holger Jon Møller, MD, PhD, Associate Professor, Consultant Dr., Department of Clinical Biochemistry at Aarhus University Hospital.

My internship from 2007 – 2011 was practiced in internal medicine, surgery and general practice.

My primary research experience comes from my PhD Study on “Marcrophage Biomarkers in Obesity and Liver Disease”, as mentioned above.

Sverre Sandberg

Professor Sverre Sandberg is director of the Norwegian quality improvement of primary care laboratories (NOKLUS) ( and, and the Norwegian Porphyria Centre (NAPOS) ( ). He has published more than 200 papers in peer reviewed journals. He is president elect of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Susanne Schnittger

Prof. Dr. rer. nat. Studied Biology at the University of Göttingen where she got her diploma and PHD both at the Institute of Human Genetics in the field of inherited malformation syndromes. In 1992-1996 she was employed in a project for characterisation of a certain leukemia subtype at the Institute of Human Genetics in Lübeck. 1996-1998 she was employed in an SFB-Program at the Hematology/Oncology department in Göttingen which also was focussing on certain leukemia subtypes. Together with Torsten Haferlach and Claudia Schoch she started the Laboratory for Leukemia Diagostics at the Klinikum Grosshadern of the Munich Ludwig-Maximillians-University in 1998 where they worked together until 2005. During this time she did her “Habilitation” in “Molecular Genetics” and her qualification as  "Expert of Human Genetics". Since August 2005 she is one of four heads of the MLL Munich Leukemia Laboratory the largest laboratory focussing solely on leukemia diagnostics worldwide. Her responsibility is the molecular diagnostic part of the MLL.

Per Simonsson

Associate professor at the Medical Faculty, Lund University. Clinical chemist at departments of clinical chemistry in Lund, Ängelholm and Malmö 1984-2014. Head of departments of clinical chemistry and laboratory medicine 1991-2008. Former chairman of Swedish and Nordic Societies of Clinical Chemistry and Huvedredaktør for Klinisk Biokemi I Norden.  Since September 2014 medical advisor at Siemens Healthcare Diagnostics. 

Henna Tyynismaa

PhD, Academy Research Fellow/Group Leader at the Research Program for Molecular Neurology, University of Helsinki. Our studies focus on understanding the molecular mechanisms of mitochondrial disease, axonal neuropathy and hereditary spastic paraplegia by applying next-generation sequencing methods to discover genetic causes of disease and by investigating mutation-specific disease models. 

Per Venge

MD and PhD and professor em in Clinical Chemistry at the University of Uppsala. He has published more than 500 papers in international journals in the areas of the biochemistry and function of neutrophils and eosinophils and conducted clinical and basic studies on asthma and allergic disease, parasitic disease, acute coronary syndromes, acute myeloid leukemia, infection-prone patients, biochemical diagnosis of acute infections and acute kidney injury.

Jørgen Viktil

Has a background as Clinical Laboratory Technician. Has been working in numerous Clinical Diagnostic Companies since 1983 through sales and management. The products that have been handled over the years have covered Clinical Chemistry, Haematology, Coagulation, Blood Gas, Electrolytes among others using most kinds of automated instruments. Since 2001 held the position as Country Manager Nordic in now, Thermo Fisher Scientific, with focus on Therapeutic Drug Monitoring and Drugs of Abuse Screening. The last 2 years – as Thermo Fisher Scientific is growing larger – as Country Manager Norway, adding also Biomarkers to the product portfolio.

Henrik Zetterberg

With a background in molecular biology and clinical chemistry, Henrik Zetterberg has spent the last 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research is translational and the biomarkers are evaluated in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. 

Johan Ärnlöv

Associate Professor of Cardiovascular Epidemiology at Uppsala University. Doctor Ärnlöv’s research focuses on the interplay between the kidney and the cardiovascular system. He is currently leading a large project aiming at discovery of novel kidney damage biomarkers. Doctor Ärnlöv has published more than 110 original articles including several papers in leading medical journals such as the New England Journal of Medicine, JAMA and Circulation.